Foghorn Therapeutics (FHTX) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genelux (GNLX) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 46.5% versus a loss of 52.7%. Foghorn Therapeutics is the larger company by market cap ($124.1 million vs $114.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | GNLX |
|---|---|---|
| Share price | $2.09 | $2.52 |
| Market cap | $124.12M | $114.02M |
| 1-day change | +6.09% | -0.79% |
| YTD return | -61.30% | -42.20% |
| 1-year return | -52.71% | -46.50% |
| 5-year return | -83.12% | — |
| EPS (TTM) | $-1.04 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $8.54 |
| 52-week low | $1.79 | $2.29 |
| Distance from 52-week high | -72.54% | -70.47% |
| Analyst consensus | buy | — |
| Avg. price target upside | +187.08% | — |
| Average volume | 611.95K | 269.67K |
| Shares outstanding | 59.39M | 45.25M |
| Employees | 106 | — |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Foghorn Therapeutics in Healthcare and Genelux in Health Care.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Healthcare · Biotechnology · 106 employees
FHTX vs GNLX FAQ
Which is bigger, Foghorn Therapeutics or Genelux?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $124.12M compared with $114.02M for Genelux (GNLX).
Which stock has performed better over the past year, FHTX or GNLX?
GNLX returned -46.50% over the past 12 months, compared with -52.71% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Genelux in the same industry?
No. Foghorn Therapeutics is in the Healthcare sector, while Genelux is in Health Care.